Evidence map›Paper›PMID 40048118›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025

Challenging the impostor: a scoping review of the pharmacological management of Capgras syndrome in Parkinson's disease and Lewy bodies dementia.

Antonina Luca, Maria Luca, Raffaele Ferri, Alessandro Serretti

Abstract readScoping Review
PubMed Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Antonina LucaDepartment of Medicine and Surgery, Kore University of Enna, Enna, Italy. antonina.luca@unikore.it.ORCID http://orcid.org/0000-0002-8397-3478
Maria LucaCentre for Addiction, Adrano-Bronte, Italy.ORCID http://orcid.org/0000-0001-5935-8283
Raffaele FerriOasi Research Institute-IRCCS, Troina, Italy.ORCID http://orcid.org/0000-0001-6937-3065
Alessandro SerrettiDepartment of Medicine and Surgery, Kore University of Enna, Enna, Italy.ORCID http://orcid.org/0000-0003-4363-3759

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCapgras syndrome (CS) is a delusional misidentification phenomenon increasingly reported in patients with Parkinson's disease (PD) and Lewy Body Dementia (LBD). Aim of the present scoping review was to provide an overview on current evidence on the pharmacological treatment of CS in PD and LBD, identifying knowledge gaps in the literature.

methodsThe following databases were consulted: PubMed, Google Scholar, the Cochrane Database and Web of Science.

resultsThe search query covered a time period from 1976 until 2022. Fourteen studies on PD (11 single case reports, 3 case series) and five on LBD (all single case reports) met the inclusion criteria. Most PD patients with CS had cognitive decline and visual hallucinations, and were managed by reducing dopaminergic therapy and prescribing neuroleptics (quetiapine, clozapine or pimavanserin), which often resulted in improvement. Neuroleptics have also been used in LBD, but with variable efficacy.

conclusionAlthough neuroleptics and dopaminergic dose adjustments appear to be beneficial for CS in PD and LBD, robust evidence is lacking. Future prospective studies are essential to establish evidence-based guidelines for this challenging syndrome.

Indexed as

Antipsychotic AgentsCapgras SyndromeLewy Body DiseaseParkinson DiseaseHumansAntipsychotic AgentsCapgras syndromeLewy bodies dementiaParkinson’s diseasePsychosis

Identifiers

PMID40048118

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.